JAPANESE COMPANIES ACTIVE INTO BIOSIMILARS MANUFACTURING

• Aska Pharmaceuticals - No major progress on the biobetter
• Asahi Glass - Entering in Biopharma CDMO Business for Global Market
• Chugai Pharmaceuticals - Entry to Authorised Biosimilar unlikely - Fighting for originator rights
• Daiichi Sankyo - Potential to be a front runner in the biosimilar space with Amgen Partnership
• Fuji Film Kyowa Kirin Biologics (FF-KKB) - Looking beyond domestic opportunities to capture global biosimilar business
• Fuji Pharma - Alvotech partnership to bolster biosimilar business as its new core in the home ground
• Gene Techno Science - JP Biopharma rising star - A reliable partner for Developing Biosimilar in Japan by Japanese Front End Companies
• Itochu Chemical Frontier Corporation - A trading house with new role in biosimilar value chain
• JCR Pharmaceuticals -A pioneer for biosimilars -now thrive in regenerative medicine & fast tracking NESP biosimilar
• Kissei - Timely launch of NESP biosimilar - Next to watch! Focus to be a niche player in BS space
• Kyowa Hakko Kirin - Tapping biosimilar market through Biosame launch -Taking advantage of front end leadership for Anemia and Heamatology therapy area
• Meiji Seika Pharma (MSP) -Trastuzumab biosimilar launch awaited in Japan- Tough competition with already approved other players!
• Mochida - Enbrel BS - first to file for Japan, now equipped with full basket for being one of the top biosimilar player in Japan
• Mitsubishi Tanabe - Not in biosimilars area yet
• MGC Pharma (now as Cultivec) - A Bio-pharmaceutical CMO - leveraging the findings gained through developing the mass-culture technology to develop biosimlars!
• Nichi-Iko - Aspiring to capture overseas markets, committed to the biosimilar business in the US
• Nipro Pharma - Not much development after Somatropin BS
• Nippon Kayaku - Pioneering New Age' of biosimilars: After Remicade - now launch of Herceptin BS is key
• Sawai - Intends to establish sales team in biosimilar field in next few years
• Towa - Still waiting for Government right policy pitch for biosimilar
• Toyobo Biologics - Eying at biosimilars CMO Business
• Takeda Teva Pharmaceuticals - Noclarity on biosimilar launch plan in Japan
• UMN Pharma - Transforming vaccines heritage into new generation biologics- but no major progress in last couple of years in biosimilar area
• Yoshindo - A steady progress for Enbrel biosimilar- Three step approach to build a Bio Company
• Sanwa Kagaku - NESP biosimilar - a therapy focus biosimilar entry for Japan market
• Amgen - Timely launch is key through Daiichi Sankyo Partnership in Japan
• Chong Kun Dang - With Fuji Pharma entering in NESP BS market